This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Monica B. Spaulding, MD; Juan Vasquez, MD; Anjum Khan, MD; Nan Sundquist, RN; John M. Loré, MD

Arch Otolaryngol. 1983;109(12):789-791.

Abstract
• A variety of adjuvant chemotherapy programs have been described for advanced head and neck cancer. The protocol described herein is nontoxic and particularly appropriate for patients with advanced tumors who cannot, because of severe pulmonary disease, tolerate bleomycin sulfate. Eighty percent of patients treated with this combination responded with more than 50% tumor shrinkage. Chemotherapy was followed by either surgery, radiation therapy, or both. Long-term control with this combined modality therapy was better in oral cavity and oropharyngeal lesions than in tumors from the hypopharynx.

(Arch Otolaryngol 1983;109:789-791)

Author Affiliations
From the Oncology Section, Buffalo Veterans Administration Medical Center (Dr Spaulding); the Departments of Medicine (Dr Spaulding), Otolaryngology (Drs Spaulding, Khan, and Loré and Ms Sundquist), Medical Oncology (Dr Vasquez), and Head and Neck Surgery (Drs Khan and Loré), State University of New York at Buffalo; and the Department of Medical Oncology, Roswell Park Memorial Institute, Buffalo (Dr Vasquez).

Footnotes
Accepted for publication April 22, 1983.

Read before the American Society of Head and Neck Surgery, Palm Springs, Calif, March 11, 1983.

Reprint requests to VA Medical Center, 3495 Bailey Ave, Buffalo, NY 14215 (Dr Spaulding).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?